Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2024.12.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Teresa Pascual Vicente und 12 weiteren Autor:innen. Beteiligte Einrichtung: General and Digestive Surgery, Cruces University Hospital, Bilbao, Spain; BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain. Hauptthemen laut MEDLINE: Liver Transplantation, Cysts, Liver Diseases. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Polycystic liver disease (PLD) is a hereditary condition, and its symptoms are due to the growth of cysts. Liver transplantation (LT) is the only curative treatment. A retrospective single-center analysis was conducted on the 10 LTs performed for PLD between 2004 and 2023. Eighty percent of the patients were women, and 70% had polycystic hepatorenal involvement. Forty percent required a kidney transplant prior to LT, and in 30%, simultaneous hepatorenal transplantation was performed due to end-stage chronic kidney failure. In 70% of cases, hepatectomy was performed with vena cava preservation (the piggy-back technique). The median operative time was 235 minutes (range 190-398), and the mean weight of the explanted liver was 5050g (range 1840-9450). Two patients had major complications classified as ≥IIIa on the Clavien-Dindo scale: a hemorrhage from the phrenic artery and a hepatic artery anastomotic stenosis, both resolved through interventional radiology. The rate of surgical reoperation and postoperative mortality was zero. The median stay in the Intensive Care Unit was 4 days (range 3-7), and the median hospital stay was 17 days (range 10-25). No patient required re-transplantation. After a median follow-up of 43.5 months (range 8-284), both patient and graft survival were 100%. Overall, and based on our experience, LT provides excellent outcomes and it is the treatment of choice for PLD in patients with end-stage liver failure or clinically limiting symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- General and Digestive Surgery, Cruces University Hospital, Bilbao, Spain; BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain.
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, Bilbao, Spain; BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain.
- BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain; Hepatology and Liver Transplantation Unit, Cruces University Hospital, Bilbao, Spain.
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, Bilbao, Spain; BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain. Electronic address: mikel.gastacamateo@osakidetza.eus.
Zitieren
APA
Vicente, T. P., Valero, A. P., Tamayo, B. V., Ordorica, P. R., Portela, G. M., Castiñeira, A. V., Gutierrez, J. E., Etxeberria, I. P., Calvo, M. P., Herrero, S. M., Bengoechea, P. S., Schneider, J. B., & Mateo, M. G. (2025). Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.12.011
Vancouver
Vicente TP, Valero AP, Tamayo BV, Ordorica PR, Portela GM, Castiñeira AV, et al. Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2024.12.011
BibTeX
@article{Vicente2025,
author = {Vicente, Teresa Pascual and Valero, Arkaitz Perfecto and Tamayo, Beatriz Villota and Ordorica, Patricia Ruiz and Portela, Gerardo Moro and Castiñeira, Alberto Ventoso and Gutierrez, Jaime Encinas and Etxeberria, Ibone Palomares and Calvo, Mikel Prieto and Herrero, Sara Mambrilla and Bengoechea, Patricia Salvador and Schneider, Javier Bustamante and Mateo, Mikel Gastaca},
title = {Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2024.12.011}
}
EUVIMED